Acusensus Stock

Acusensus Equity

The The Equity of Acusensus (ACE.AX) as of Jul 31, 2026 is 46.79 M AUD. In the previous year, The Equity was 35.92 M AUD — a change of 30.25% (higher).

Equity

46.79 MAUD

YoY

30.25%

Last updated:

In 2026, Acusensus's equity was 46.79 M AUD, a 30.25% increase from the 35.92 M AUD equity in the previous year.

Access this data via the Eulerpool API

Acusensus Stock analysis

What does Acusensus do? Acusensus is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Acusensus's Equity

Acusensus's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Acusensus's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Acusensus's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Acusensus's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Acusensus’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Acusensus stock

The Equity of Acusensus is 46.79 M AUD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Acusensus

All Key Metrics — Acusensus